Afleveringen
-
Cynthia Pussinen, CEO of Sernova, describes their innovative cell therapy platform, the Cell Pouch System, which can deliver functional cures for chronic diseases using therapeutic cells, tissues, proteins, and other molecules. This implantable device is made of mesh that allows for vascularization, forming a pseudo-organ that can function in the body and fulfill unmet needs. The current focus is on type one diabetes, where the Cell Pouch has shown promising results, allowing patients to become insulin-independent. Other potential applications include treating hypothyroidism and hemophilia A.
Cynthia explains, "The Cell Pouch is a very flexible implantable device. It's made of two polypropylene mesh sheets, and in those mesh sheets, it has perfectly sized pores. So, the Cell Pouch is a couple of millimeters thick and about the size of a credit card."
"We take the Cell Pouch and, place it in the abdominal region of the patient and let it sit for a couple of weeks. And that is to allow vascularization. So vessels and tissues grow through those pores I mentioned a moment ago of the Cell Pouch. It creates a very healthy environment for us to put those therapeutic cells or tissues or blood factors, hormones, or proteins into that Cell Pouch a couple of weeks later after that full vascularization has happened. If we put the cells in without the vascularization happening first, the cells would die."
"After we place those therapeutic cells into the Cell Pouch, the cells in the Cell Pouch essentially form a pseudo-organ of sorts. They begin to function, fulfilling what the body was not capable of previously performing. And so in the case of our type one diabetes study, what happens is, after the Cell Pouch and cells are implanted into the patient's body, we then begin to titrate them off of insulin over the course of a couple of weeks. Then the body with the Cell Pouch and cells goes on to essentially form that pseudo-organ of sorts. We have patients now who have been insulin-independent for a number of years."
#Sernova #FunctionalCure #TypeOneDiabetes #CellTherapy #ChronicDiseases #PrecisionMedicine #Medtech
Sernova.com
Listen to the podcast here
-
Cynthia Pussinen, CEO of Sernova, describes their innovative cell therapy platform, the Cell Pouch System, which can deliver functional cures for chronic diseases using therapeutic cells, tissues, proteins, and other molecules. This implantable device is made of mesh that allows for vascularization, forming a pseudo-organ that can function in the body and fulfill unmet needs. The current focus is on type one diabetes, where the Cell Pouch has shown promising results, allowing patients to become insulin-independent. Other potential applications include treating hypothyroidism and hemophilia A.
Cynthia explains, "The Cell Pouch is a very flexible implantable device. It's made of two polypropylene mesh sheets, and in those mesh sheets, it has perfectly sized pores. So, the Cell Pouch is a couple of millimeters thick and about the size of a credit card."
"We take the Cell Pouch and, place it in the abdominal region of the patient and let it sit for a couple of weeks. And that is to allow vascularization. So vessels and tissues grow through those pores I mentioned a moment ago of the Cell Pouch. It creates a very healthy environment for us to put those therapeutic cells or tissues or blood factors, hormones, or proteins into that Cell Pouch a couple of weeks later after that full vascularization has happened. If we put the cells in without the vascularization happening first, the cells would die."
"After we place those therapeutic cells into the Cell Pouch, the cells in the Cell Pouch essentially form a pseudo-organ of sorts. They begin to function, fulfilling what the body was not capable of previously performing. And so in the case of our type one diabetes study, what happens is, after the Cell Pouch and cells are implanted into the patient's body, we then begin to titrate them off of insulin over the course of a couple of weeks. Then the body with the Cell Pouch and cells goes on to essentially form that pseudo-organ of sorts. We have patients now who have been insulin-independent for a number of years."
#Sernova #FunctionalCure #TypeOneDiabetes #CellTherapy #ChronicDiseases #PrecisionMedicine #Medtech
Sernova.com
Download the transcript here
-
Zijn er afleveringen die ontbreken?
-
Dr. Ben Barlow, Chief Medical Officer of Experity, has identified opportunities to leverage the power of technology in the complex urgent care environment, which requires a wide range of services. To overcome the challenges of long wait times and staffing shortages, Experity is streamlining workflows and making urgent care more efficient and patient-centered. Online scheduling, pre-visit information gathering, and access to existing electronic health records aid clinicians in treatment decisions and post-visit follow-up, resulting in improved delivery of on-demand healthcare services.
Ben explains, "We do a lot of different things. I don't think people know what we do in urgent care. We started being an alternative for patients to the emergency department, but now we've evolved into being patient-centered to where the doctor waits on the patient. And so, that's what we do in urgent care. We take care of a lot of different needs of the patients, really dictated on what the patients want us to help them with."
"I think that urgent care's strength is that we continue to think about the challenges the patients are experiencing and try to adapt to those challenges. An example is recently, when COVID hit, no one wanted to wait in lobbies. They didn't want to interact with other sick people. So urgent care ramped up its online scheduling, allowing patients to get on a waitlist online and then get texted when it was their time to come in. And so it's those kinds of things that, as challenges arise, the urgent care community is looking to address. Our major challenge right now is looking at the payer system, challenges with reimbursement, labor shortages, and things like that."
"We want to think of the patient as not just the interaction that occurs inside the clinic but also before and after because the medical community and the healthcare environment are very complicated to navigate. We feel like urgent care is the front door into the system, so we're continuing to make products and services that help our clients help patients navigate the complexities of the healthcare environment."
#Experity #UrgentCare #PatientExperience #Healthcare
experityhealth.com
Listen to the podcast here
-
Dr. Ben Barlow, Chief Medical Officer of Experity, has identified opportunities to leverage the power of technology in the complex urgent care environment, which requires a wide range of services. To overcome the challenges of long wait times and staffing shortages, Experity is streamlining workflows and making urgent care more efficient and patient-centered. Online scheduling, pre-visit information gathering, and access to existing electronic health records aid clinicians in treatment decisions and post-visit follow-up, resulting in improved delivery of on-demand healthcare services.
Ben explains, "We do a lot of different things. I don't think people know what we do in urgent care. We started being an alternative for patients to the emergency department, but now we've evolved into being patient-centered to where the doctor waits on the patient. And so, that's what we do in urgent care. We take care of a lot of different needs of the patients, really dictated on what the patients want us to help them with."
"I think that urgent care's strength is that we continue to think about the challenges the patients are experiencing and try to adapt to those challenges. An example is recently, when COVID hit, no one wanted to wait in lobbies. They didn't want to interact with other sick people. So urgent care ramped up its online scheduling, allowing patients to get on a waitlist online and then get texted when it was their time to come in. And so it's those kinds of things that, as challenges arise, the urgent care community is looking to address. Our major challenge right now is looking at the payer system, challenges with reimbursement, labor shortages, and things like that."
"We want to think of the patient as not just the interaction that occurs inside the clinic but also before and after because the medical community and the healthcare environment are very complicated to navigate. We feel like urgent care is the front door into the system, so we're continuing to make products and services that help our clients help patients navigate the complexities of the healthcare environment."
#Experity #UrgentCare #PatientExperience #Healthcare
experityhealth.com
Download the transcript here
-
Meg Boehme, living with multiple sclerosis and a friend, discusses her reaction to receiving the diagnosis of MS, which she had suspected for many years due to little-understood symptoms. Meg highlights the importance of doctors being aware of the early indications of MS and helping patients see this as a chronic condition that can, in part, be treated with lifestyle changes and staying active. She also emphasizes the need for more affordable access to the latest treatments.
Meg explains, "Oh, yes. It is a chronic condition. What annoys me is that in the media, it's often treated as a fatal condition. And for most of us, for those who don't have the progressive form, it fortunately is not. It doesn't have to be. The diagnosis is not necessarily the end of the world."
"There are good treatments coming down the road. The key to it is keeping yourself active and keeping your own body as healthy as you can. Eating well, staying active, keeping your weight manageable, keeping your diet manageable. Don't do stupid things. That being responsible for your own body, being responsible for your own life. When you get a diagnosis of anything like this, you need to take a look and know that you need to take care of yourself."
"It's a lifesaver, quite literally. I'll go into the chorus in pain, and the pain disappears. Singing is, in all ways, the lifeblood of me. And yes, the singing, the breathing, the posture, the fact that I stand on the risers for three hours a week, that it keeps my brain active, that I have to learn the music. We sing completely acapella. We have about three weeks to learn a piece of music and then sing without looking at the music. And that my director has MS and is not sympathetic towards me. If I'm dizzy or have a problem, I can sit, but I mostly don't. I gut it out. But if I come in pain, most of the time, I don't leave in pain. It's just the thing that keeps me going, and I think the big thing is that it keeps my brain active."
#MS #MultipleSclerosis #ChronicDiseases
Listen to the podcast here
-
Meg Boehme, living with multiple sclerosis and a friend, discusses her reaction to receiving the diagnosis of MS, which she had suspected for many years due to little-understood symptoms. Meg highlights the importance of doctors being aware of the early indications of MS and helping patients see this as a chronic condition that can, in part, be treated with lifestyle changes and staying active. She also emphasizes the need for more affordable access to the latest treatments.
Meg explains, "Oh, yes. It is a chronic condition. What annoys me is that in the media, it's often treated as a fatal condition. And for most of us, for those who don't have the progressive form, it fortunately is not. It doesn't have to be. The diagnosis is not necessarily the end of the world."
"There are good treatments coming down the road. The key to it is keeping yourself active and keeping your own body as healthy as you can. Eating well, staying active, keeping your weight manageable, keeping your diet manageable. Don't do stupid things. That being responsible for your own body, being responsible for your own life. When you get a diagnosis of anything like this, you need to take a look and know that you need to take care of yourself."
"It's a lifesaver, quite literally. I'll go into the chorus in pain, and the pain disappears. Singing is, in all ways, the lifeblood of me. And yes, the singing, the breathing, the posture, the fact that I stand on the risers for three hours a week, that it keeps my brain active, that I have to learn the music. We sing completely acapella. We have about three weeks to learn a piece of music and then sing without looking at the music. And that my director has MS and is not sympathetic towards me. If I'm dizzy or have a problem, I can sit, but I mostly don't. I gut it out. But if I come in pain, most of the time, I don't leave in pain. It's just the thing that keeps me going, and I think the big thing is that it keeps my brain active."
#MS #MultipleSclerosis #ChronicDiseases
Download the transcript here
-
Kinsey Fabrizio, now President of the Consumer Technology Association, highlights many digital health innovations in the women's health arena showcased in the recent CES 2024 event. A recent CTA study found that 45% of women currently use digital health solutions, and 75% of women in the survey face challenges obtaining healthcare services. With oversight from the FDA, medical devices and wearables are becoming increasingly accurate. With the addition of AI, they are expected to play a role in improving healthcare outcomes and access.
Kinsey explains, "CTA is a nonprofit trade association, and we represent the entire consumer technology industry. And a big part of that is digital health. We have members who are digital health companies, and we strive to help advance the industry for them. We do that through policy, research, and standards development. We're an ANSI-Accredited Standards organization, and through different events, we convene the industry together."
"We saw a lot of really exciting innovations in women's health at the CES 2024 show. Digital health is always a really big category for CES. We have hundreds of exhibitors in this category, and we do two full days of conference programming called our Digital Health Summit. And it's an opportunity for the industry to come together and talk about the exciting transformation of healthcare led by technology. But some really exciting products that we saw in the women's health space were just unique and stood out."
"That is just an example of how tech is starting to be tailored to address specific women's health issues. This isn't something I would've seen at CES 10 years ago, so it shows the evolution and advancement there. Another product that I thought was just game-changing is Cerviray, a cancer screening device by AIDOT, which utilizes a very specific technique called visual inspection with acetic acid. And it's faster, simpler, and less invasive than traditional tests like the pap smear."
#CTA #ConsumerTechnologyAssociation #EmpowerHerHealth #AIforHerHealth #EmpowHERHealth #FutureofFeminineHealth
cta.tech
Listen to the podcast here
-
Kinsey Fabrizio, now President of the Consumer Technology Association, highlights many digital health innovations in the women's health arena showcased in the recent CES 2024 event. A recent CTA study found that 45% of women currently use digital health solutions, and 75% of women in the survey face challenges obtaining healthcare services. With oversight from the FDA, medical devices and wearables are becoming increasingly accurate. With the addition of AI, they are expected to play a role in improving healthcare outcomes and access.
Kinsey explains, "CTA is a nonprofit trade association, and we represent the entire consumer technology industry. And a big part of that is digital health. We have members who are digital health companies, and we strive to help advance the industry for them. We do that through policy, research, and standards development. We're an ANSI-Accredited Standards organization, and through different events, we convene the industry together."
"We saw a lot of really exciting innovations in women's health at the CES 2024 show. Digital health is always a really big category for CES. We have hundreds of exhibitors in this category, and we do two full days of conference programming called our Digital Health Summit. And it's an opportunity for the industry to come together and talk about the exciting transformation of healthcare led by technology. But some really exciting products that we saw in the women's health space were just unique and stood out."
"That is just an example of how tech is starting to be tailored to address specific women's health issues. This isn't something I would've seen at CES 10 years ago, so it shows the evolution and advancement there. Another product that I thought was just game-changing is Cerviray, a cancer screening device by AIDOT, which utilizes a very specific technique called visual inspection with acetic acid. And it's faster, simpler, and less invasive than traditional tests like the pap smear."
#CTA #ConsumerTechnologyAssociation #EmpowerHerHealth #AIforHerHealth #EmpowHERHealth #FutureofFeminineHealth
cta.tech
Download the transcript here
-
Dahlia Attia-King, CEO of Panacea, is bringing whole exome sequencing to a broader audience and promoting the value of this data for disease prevention and making smarter lifestyle choices. She highlights the differences between whole exome sequencing and whole genome sequencing, noting that whole exome sequencing can be conducted more cost-effectively and provide information about the genes most likely to impact health.
Dahlia explains, "These two barriers, the physicians and the insurers, are sometimes big barriers to accessing clinical genetic testing for people, even those who need it and those who fit the current guidelines. We aim to bypass those barriers and partner with very skilled CLIA/CAP certified laboratories. We partner with trained clinical genetic counselors. We partner with physicians who understand how to utilize genetic testing, and we bring those services collectively in one very simple, user-friendly experience so that no one who wants genetic testing will struggle to get it."
"We do that and focus on whole exome because, number one, it's more cost-effective. It's actually quite a lot more expensive to sequence the entire genome. So when you focus on just the genes, you focus on the 20,000 plus genes in the genome and nothing else. But that's so valuable because the vast majority of changes or mutations in your genome that affect your susceptibility for disease happen in the exome."
"But to your point, there is also a large amount of data that can come off the exome that is interpretable. And in a lot of cases, just like you said, it's actionable, which means that information can be used to make certain targeted decisions in your healthcare so that you can essentially, in a way, get ahead of your genes or outsmart your genes because you're prepared. You know the instructions that your genes are holding and where your risks might be. That way, you can certainly better target your healthcare and take a more preventative approach as opposed to a reactionary approach, which happens in most cases in today's healthcare."
#SeekPanacea #WholeExomeSequencing #WholeGenomeSequencing #Genome #PreventativeMedicine
seekpanacea.com
Listen to the podcast here
-
Dahlia Attia-King, CEO of Panacea, is bringing whole exome sequencing to a broader audience and promoting the value of this data for disease prevention and making smarter lifestyle choices. She highlights the differences between whole exome sequencing and whole genome sequencing, noting that whole exome sequencing can be conducted more cost-effectively and provide information about the genes most likely to impact health.
Dahlia explains, "These two barriers, the physicians and the insurers, are sometimes big barriers to accessing clinical genetic testing for people, even those who need it and those who fit the current guidelines. We aim to bypass those barriers and partner with very skilled CLIA/CAP certified laboratories. We partner with trained clinical genetic counselors. We partner with physicians who understand how to utilize genetic testing, and we bring those services collectively in one very simple, user-friendly experience so that no one who wants genetic testing will struggle to get it."
"We do that and focus on whole exome because, number one, it's more cost-effective. It's actually quite a lot more expensive to sequence the entire genome. So when you focus on just the genes, you focus on the 20,000 plus genes in the genome and nothing else. But that's so valuable because the vast majority of changes or mutations in your genome that affect your susceptibility for disease happen in the exome."
"But to your point, there is also a large amount of data that can come off the exome that is interpretable. And in a lot of cases, just like you said, it's actionable, which means that information can be used to make certain targeted decisions in your healthcare so that you can essentially, in a way, get ahead of your genes or outsmart your genes because you're prepared. You know the instructions that your genes are holding and where your risks might be. That way, you can certainly better target your healthcare and take a more preventative approach as opposed to a reactionary approach, which happens in most cases in today's healthcare."
#SeekPanacea #WholeExomeSequencing #WholeGenomeSequencing #Genome #PreventativeMedicine
seekpanacea.com
Download the transcript here
-
Steven Lee, Co-Founder and CEO of Ianacare, is in the business of supporting caregivers by working with employers, health plans, and providers to offer services that patients and their families need. Effective hospital-at-home and home non-clinical care models show a reduction in hospital readmission and cost of care. This care navigator approach allows caregivers to keep patients in their homes and reduces employee absenteeism. Working with partners, Ianacare has applied to be an approved provider in the new CMS program GUIDE, the Guiding and Improved Dementia Experience program, to expand the application of this model.
Steven explains, "This has become really critical. For one reason, good caregiving in the home keeps patients in the home and out of institutions. And that's a win-win-win for everybody. Patients prefer being in the familiar surroundings of their home. We all would prefer to age in our own homes. It's cheaper for the healthcare system. Every inpatient admission or ER visit prevented by a family care member is thousands of dollars saved in the healthcare system."
"So it's really a win-win-win. The numbers and the research out there clearly prove these caregivers' critical role. I'll cite a couple of studies. There's a UPMC study that shows when family caregivers are involved and engaged in care plans, hospital readmissions decrease by 25%. Conversely, there's a study from the Journal of American Geriatric Society when patients have caregivers who are depressed, burnt out, or tired, they experienced a 73% increase in ED utilization and $2,000 higher medical costs over six months. So, to summarize, good caregiving keeps patients in the home, and that's why this is important."
"What we've done is bring together all the layers of resources you might need at some point in the care journey into one easy-to-use experience. We have a platform accessible through a browser or smartphone, and it starts by matching you up with unlimited access to a care navigator who's your right-hand expert to not only guide you through decisions and planning but also ensure things get done."
#Ianacare #Caregivers #HospitalatHome #HospitalReadmission #CareNavigators #CMSGUIDE #AlzheimersDisease
Ianacare.com
Listen to the podcast here
-
Steven Lee, Co-Founder and CEO of Ianacare, is in the business of supporting caregivers by working with employers, health plans, and providers to offer services that patients and their families need. Effective hospital-at-home and home non-clinical care models show a reduction in hospital readmission and cost of care. This care navigator approach allows caregivers to keep patients in their homes and reduces employee absenteeism. Working with partners, Ianacare has applied to be an approved provider in the new CMS program GUIDE, the Guiding and Improved Dementia Experience program, to expand the application of this model.
Steven explains, "This has become really critical. For one reason, good caregiving in the home keeps patients in the home and out of institutions. And that's a win-win-win for everybody. Patients prefer being in the familiar surroundings of their home. We all would prefer to age in our own homes. It's cheaper for the healthcare system. Every inpatient admission or ER visit prevented by a family care member is thousands of dollars saved in the healthcare system."
"So it's really a win-win-win. The numbers and the research out there clearly prove these caregivers' critical role. I'll cite a couple of studies. There's a UPMC study that shows when family caregivers are involved and engaged in care plans, hospital readmissions decrease by 25%. Conversely, there's a study from the Journal of American Geriatric Society when patients have caregivers who are depressed, burnt out, or tired, they experienced a 73% increase in ED utilization and $2,000 higher medical costs over six months. So, to summarize, good caregiving keeps patients in the home, and that's why this is important."
"What we've done is bring together all the layers of resources you might need at some point in the care journey into one easy-to-use experience. We have a platform accessible through a browser or smartphone, and it starts by matching you up with unlimited access to a care navigator who's your right-hand expert to not only guide you through decisions and planning but also ensure things get done."
#Ianacare #Caregivers #HospitalatHome #HospitalReadmission #CareNavigators #CMSGUIDE #AlzheimersDisease
Ianacare.com
Download the transcript here
-
Stella Vnook, the Founder and President, and Bill Breitenbach, CEO of Oral Bio Life, talk about the prevalence and causes of periodontal disease and the limitations of current treatments. The Oral Bio Life PiezoGEL technology has shown effective removal of plaque and treatment of bacteria on teeth and regenerating bone for a long-term solution. Periodontal disease contributes to inflammation and infection and is showing links to other health conditions like cancer, heart disease, diabetes, and Alzheimer's disease. In addition to human trials, success is seen in trials with veterinarians to regenerate bone in dogs.
Stella Vnook elaborates, "Dentists can identify the early warning signs, but in addition to oral hygiene, we also found, and it's supported by data, there are some people who are predisposed to just having issues with their gums and/or periodontal disease. There are genetic implications, and there are people that have comorbidities. The goal is to remove the plaque and the bacteria film. But the process is rather painful. One of the reasons why I founded this technology and this company is because of the scaling and root planing, which is quite painful."
Bill explains, "I'd like to add there's a real recognition lately from scientists around the world that inflammation is the root cause of a lot of major diseases - cancer, heart disease, diabetes, and even Alzheimer's. What they're finding is that the fibrous bacteria travel from the mouth throughout the body, contributing to heart disease, diabetes, pregnancy complications, cancer, and Alzheimer's. Just recently, there's some NIH data that shows that P. gingivitis, the main pathogen for chronic gum disease, has been identified in the brain of Alzheimer's disease patients. So, it's not just about gum disease, it's about total body health, and there is a need to be taking care of that and being mindful of the downstream effects of not taking care of periodontal disease."
#OralBioLife #GumDisease #PeriodontalDisease #Inflammation #Veterinarians #BoneRegeneration
oralbiolife.com
Listen to the podcast here
-
Stella Vnook, the Founder and President, and Bill Breitenbach, CEO of Oral Bio Life, talk about the prevalence and causes of periodontal disease and the limitations of current treatments. The Oral Bio Life PiezoGEL technology has shown effective removal of plaque and treatment of bacteria on teeth and regenerating bone for a long-term solution. Periodontal disease contributes to inflammation and infection and is showing links to other health conditions like cancer, heart disease, diabetes, and Alzheimer's disease. In addition to human trials, success is seen in trials with veterinarians to regenerate bone in dogs.
Stella Vnook elaborates, "Dentists can identify the early warning signs, but in addition to oral hygiene, we also found, and it's supported by data, there are some people who are predisposed to just having issues with their gums and/or periodontal disease. There are genetic implications, and there are people that have comorbidities. The goal is to remove the plaque and the bacteria film. But the process is rather painful. One of the reasons why I founded this technology and this company is because of the scaling and root planing, which is quite painful."
Bill explains, "I'd like to add there's a real recognition lately from scientists around the world that inflammation is the root cause of a lot of major diseases - cancer, heart disease, diabetes, and even Alzheimer's. What they're finding is that the fibrous bacteria travel from the mouth throughout the body, contributing to heart disease, diabetes, pregnancy complications, cancer, and Alzheimer's. Just recently, there's some NIH data that shows that P. gingivitis, the main pathogen for chronic gum disease, has been identified in the brain of Alzheimer's disease patients. So, it's not just about gum disease, it's about total body health, and there is a need to be taking care of that and being mindful of the downstream effects of not taking care of periodontal disease."
#OralBioLife #GumDisease #PeriodontalDisease #Inflammation #Veterinarians #BoneRegeneration
oralbiolife.com
Download the transcript here
-
Chuck Rinker, CEO of PRSONAS, sees the next-generation workforce of digital healthcare components as digital personalities and avatars that will act as patient advocates and improve the communications between patients and clinicians. With an emphasis on building trust and showing empathy, these digital tools help gather accurate information and break down language and cultural barriers. Avatars can be customized for locations like hospital lobbies and purposes like clinical trial recruitment. With a background in game programming, Chuck brings a deep knowledge of how the emotional bond between gamers and avatars can be applied to building more robust patient engagement.
Chuck explains, "Since technology has been predominant in the healthcare space, we've always had to teach people how to use technology, and the barrier is communication. So, we've said, well, let's just take a different approach. We're not trying to recreate humans, and we're not trying to replace humans. We're just trying to teach all this technology, this scalable healthcare, this improvement in healthcare technology that we have, and make it so that it can communicate to us as humans. We naturally communicate as humans. We don't naturally communicate as an IT specialist, so we're trying to flip it on its head and work it the other way around."
"That was a concept we started way back in 2013. We originally built a few of these as product specialists in the pharmaceutical drug launch space. I think Genentech and Pfizer were probably the first ones to use it. It was meant to support the healthcare professionals. Okay, what's all the information you have, from prescribing information to all the complexities of a mechanism of disease and all that you have to relay over and over and over during a multiphase pharmaceutical launch? So, we built these repeatable humans to be those domain experts."
"We've learned along the way that it was a great, wonderful piece but that the patients themselves are the ones who are getting "lost in the mix." So, our units are trained to speak whatever language is used by the patient population you're targeting. They can be culturally diverse. We do Sign Language - American Sign Language and British Sign Language. So it's really about creating that advocate, breaking down that communication barrier so that every patient feels represented and welcomed and has their own patient advocate to help them through that healthcare journey."
#PRSONAS #Avatars #DigitalPersonalities #DigitalHealth #AI #PatientAdvocate #PatientEngagement #ClinicalTrials
PRSONAS.com
Listen to the podcast here
-
Chuck Rinker, CEO of PRSONAS, sees the next-generation workforce of digital healthcare components as digital personalities and avatars that will act as patient advocates and improve the communications between patients and clinicians. With an emphasis on building trust and showing empathy, these digital tools help gather accurate information and break down language and cultural barriers. Avatars can be customized for locations like hospital lobbies and purposes like clinical trial recruitment. With a background in game programming, Chuck brings a deep knowledge of how the emotional bond between gamers and avatars can be applied to building more robust patient engagement.
Chuck explains, "Since technology has been predominant in the healthcare space, we've always had to teach people how to use technology, and the barrier is communication. So, we've said, well, let's just take a different approach. We're not trying to recreate humans, and we're not trying to replace humans. We're just trying to teach all this technology, this scalable healthcare, this improvement in healthcare technology that we have, and make it so that it can communicate to us as humans. We naturally communicate as humans. We don't naturally communicate as an IT specialist, so we're trying to flip it on its head and work it the other way around."
"That was a concept we started way back in 2013. We originally built a few of these as product specialists in the pharmaceutical drug launch space. I think Genentech and Pfizer were probably the first ones to use it. It was meant to support the healthcare professionals. Okay, what's all the information you have, from prescribing information to all the complexities of a mechanism of disease and all that you have to relay over and over and over during a multiphase pharmaceutical launch? So, we built these repeatable humans to be those domain experts."
"We've learned along the way that it was a great, wonderful piece but that the patients themselves are the ones who are getting "lost in the mix." So, our units are trained to speak whatever language is used by the patient population you're targeting. They can be culturally diverse. We do Sign Language - American Sign Language and British Sign Language. So it's really about creating that advocate, breaking down that communication barrier so that every patient feels represented and welcomed and has their own patient advocate to help them through that healthcare journey."
#PRSONAS #Avatars #DigitalPersonalities #DigitalHealth #AI #PatientAdvocate #PatientEngagement #ClinicalTrials
PRSONAS.com
Download the transcript here
-
Cody Shandraw, President and Co-Founder of Healing Realty Trust, aims to provide robust mental and behavioral health treatment facilities. The lack of infrastructure has been a significant hurdle for expanding the commercialization of drugs that require longer in-office visits and space to accommodate the needs of patients undergoing treatments. The emerging field of psychedelics for treating neurological conditions like PTSD requires clinicians to understand the physical requirements for treatment facilities to provide privacy and comfort during the extended time necessary for many of these treatments.
Cody explains, "In 2020, it was a really interesting stat that I was made aware of at one of the conferences down here in Miami. It was around a drug called Spravato, which is an intranasal ketamine drug. And they were very excited about the launch. It was in development for quite some time, and unfortunately, it didn't commercialize, I think, to their expectations. I asked one of the drug reps down here in Florida why he thought that was, and he said it was a really simple answer: the lack of infrastructure."
"It's a unique drug, and we've only seen this a couple of times. Maybe proton therapy or dialysis centers where when a new therapy is approved, you need that infrastructure to go along with that therapy. And that is what Spravato was. You actually had to be in a clinic for two hours after administration for Spravato. So it was a very unique thing. And a lot of the legacy behavioral mental health providers that would be the target market for that drug, they didn't want to disrupt normal patient inflows into their clinic. So it took a couple of years. When that drug was launched, there were less than a hundred clinics in the United States offering that. Today, there are 2,700 of those clinics, and now Spravato is a blockbuster drug."
#HealingRealtyTrust #CommercialRealEstate #BehavioralHealth #EmergingTherapies #PsychedelicAssistedTherapy #PatientAccess #HealthcareInfrastructure #ImprovingBehavioralHealth
HealingRT.com
Listen to the podcast here
-
Cody Shandraw, President and Co-Founder of Healing Realty Trust, aims to provide robust mental and behavioral health treatment facilities. The lack of infrastructure has been a significant hurdle for expanding the commercialization of drugs that require longer in-office visits and space to accommodate the needs of patients undergoing treatments. The emerging field of psychedelics for treating neurological conditions like PTSD requires clinicians to understand the physical requirements for treatment facilities to provide privacy and comfort during the extended time necessary for many of these treatments.
Cody explains, "In 2020, it was a really interesting stat that I was made aware of at one of the conferences down here in Miami. It was around a drug called Spravato, which is an intranasal ketamine drug. And they were very excited about the launch. It was in development for quite some time, and unfortunately, it didn't commercialize, I think, to their expectations. I asked one of the drug reps down here in Florida why he thought that was, and he said it was a really simple answer: the lack of infrastructure."
"It's a unique drug, and we've only seen this a couple of times. Maybe proton therapy or dialysis centers where when a new therapy is approved, you need that infrastructure to go along with that therapy. And that is what Spravato was. You actually had to be in a clinic for two hours after administration for Spravato. So it was a very unique thing. And a lot of the legacy behavioral mental health providers that would be the target market for that drug, they didn't want to disrupt normal patient inflows into their clinic. So it took a couple of years. When that drug was launched, there were less than a hundred clinics in the United States offering that. Today, there are 2,700 of those clinics, and now Spravato is a blockbuster drug."
#HealingRealtyTrust #CommercialRealEstate #BehavioralHealth #EmergingTherapies #PsychedelicAssistedTherapy #PatientAccess #HealthcareInfrastructure #ImprovingBehavioralHealth
HealingRT.com
Download the transcript here
-
Fengru Lin, Co-Founder and CEO of TurtleTree, is applying precision fermentation technology to produce high-value ingredients for food and beverages without the need for animals. This biotech company's first goal is to expand the production of lactoferrin, a protein found in small quantities in milk that has been shown to promote gut health and immunity. Finding a scalable way to produce lactoferrin will lead to adding this iron-binding element to plant-based milks and energy drinks.
Fengru explains, "A couple of years ago, I was learning how to make cheese as a hobby. It was quite a fanatic period of time. I went up to Vermont from Singapore for a couple of weeks to learn how to make cheese and I wanted to replicate this whole process back in Singapore. But in Singapore, we have no access to cows, we have no access to raw, fresh milk. So, I had to go down to Indonesia and Thailand to look for milk. In this journey, I was exposed to a lot of challenges around the dairy industry, things like contract farming, things like antibiotics, and hormones being pumped into the cows. As a result, the milk quality always suffers, the mozzarella couldn't stretch, it's not enough calcium, not enough nutrients in the milk. So, I gave up that whole idea and was still working for Google."
"So, we bootstrapped initially, brought in some scientists, did a lot of research, and filed our first patent. The technology requires getting memory cells and culturing the cells to express full-function milk, all 2,000 different ingredients in milk. We had our early success and quickly brought this technology to some of the biggest dairy companies in the world, folks like Fonterra and Abbott, and told them, "Hey, we can make milk. What do you think?"
"Very quickly they came back with feedback saying, "Well, great that you can make milk, but milk is $2 a gallon. I don't think you can get to the price point anytime soon. You should really be focused on high-value ingredients that are found in milk." So they gave us a list of half a dozen proteins and ingredients that we should look at, and at the top of the list is lactoferrin because of all these great benefits and the high price point it is today. You guys should be focused on the high-value ingredients that are low in supply across the market so you can address this accessibility problem and not try to reproduce a commodity like milk. So that's how we started and where we are today. We just got our FDA Self GRAS status in November last year, so we've started to commercialize this lactoferrin."
#TurtleTree #FunctionalFood #Lactoferrin #Protein #PrecisionFermentation #Milk #SustainableFoodProduction #Nutrition
turtletree.com
Listen to the podcast here
-
Fengru Lin, Co-Founder and CEO of TurtleTree, is applying precision fermentation technology to produce high-value ingredients for food and beverages without the need for animals. This biotech company's first goal is to expand the production of lactoferrin, a protein found in small quantities in milk that has been shown to promote gut health and immunity. Finding a scalable way to produce lactoferrin will lead to adding this iron-binding element to plant-based milks and energy drinks.
Fengru explains, "A couple of years ago, I was learning how to make cheese as a hobby. It was quite a fanatic period of time. I went up to Vermont from Singapore for a couple of weeks to learn how to make cheese and I wanted to replicate this whole process back in Singapore. But in Singapore, we have no access to cows, we have no access to raw, fresh milk. So, I had to go down to Indonesia and Thailand to look for milk. In this journey, I was exposed to a lot of challenges around the dairy industry, things like contract farming, things like antibiotics, and hormones being pumped into the cows. As a result, the milk quality always suffers, the mozzarella couldn't stretch, it's not enough calcium, not enough nutrients in the milk. So, I gave up that whole idea and was still working for Google."
"So, we bootstrapped initially, brought in some scientists, did a lot of research, and filed our first patent. The technology requires getting memory cells and culturing the cells to express full-function milk, all 2,000 different ingredients in milk. We had our early success and quickly brought this technology to some of the biggest dairy companies in the world, folks like Fonterra and Abbott, and told them, "Hey, we can make milk. What do you think?"
"Very quickly they came back with feedback saying, "Well, great that you can make milk, but milk is $2 a gallon. I don't think you can get to the price point anytime soon. You should really be focused on high-value ingredients that are found in milk." So they gave us a list of half a dozen proteins and ingredients that we should look at, and at the top of the list is lactoferrin because of all these great benefits and the high price point it is today. You guys should be focused on the high-value ingredients that are low in supply across the market so you can address this accessibility problem and not try to reproduce a commodity like milk. So that's how we started and where we are today. We just got our FDA Self GRAS status in November last year, so we've started to commercialize this lactoferrin."
#TurtleTree #FunctionalFood #Lactoferrin #Protein #PrecisionFermentation #Milk #SustainableFoodProduction #Nutrition
turtletree.com
Download the transcript here
- Laat meer zien
